Publikationsdatenbank

Filter zurücksetzen
Titel
Studie
Jahr

Everolimus as second-line therapy for metastatic renal cell carcinoma: final results of phase IV study MARC-2.

M. Staehler, D. Christoph, M. Stöckle, J. Harde, A. Stenzl, D. Klein, I. Benz-Rüd, V. Grünwald, 2018.

Oncol Res Treat 41 (suppl 4)(P610).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

MARC-2
2018

Final results from IMPROVE: A randomized, controlled, open-label, cross-over phase IV study to determine the patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab for advanced HR+/HER2- breast cancer.

Decker T, Söling U, Hahn A, Maintz C, Kurbacher CM, Rieger L, Chiabudini M, Falkenstein J, Runkel E, Potthoff K., 2018.

Oncol Res Treat 41 (suppl 4)(P916).

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

IMPROVE
2018

Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PRO Kidney registry.

Kirste, T., Werner, T., Scheffler, M., Hamm, N., Eckert, R., Pelz, H., Fichter, C., Müller, L., Sahlmann, J., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P608).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PRO Kidney
2018

Nab-paclitaxel in combination with carboplatin as first line therapy for patients with stage IIIB/IV NSCLC in the real-world setting: Interim results of the NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Schulz, H., Janssen, J., Chiabudini, M., Koszinowski, S., Potthoff, K., Lang, S., Runkel, E., 2018.

Oncol Res Treat 41 (suppl 4)(P912).

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NEPTUN
2018

First-line pazopanib in poor-risk patients with metastatic renal cell carcinoma.

Staehler, M., Panic, A., Merling, M., Vannier, C., Hermann, E., Hogrefe, C., Potthoff, K., Grünwald, V., 2018.

Oncol Res Treat 41 (suppl 4)(P606).

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

FLIPPER
2018

Palbociclib in combination with letrozole as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welslau, M., Zaiss, M., Söling, U., Untch, M., Müller, L., Lüftner, D., Meiler, J., Welt, A., Sahlmann, J., Houet, L., Runkel, E., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P919).

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

INGE-B
2018

An observational study to evaluate the effectiveness of OnLife® in improving chemotherapy-induced peripheral neuropathy in patients with colon or breast cancer after end of adjuvant therapy: Design of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P945).

Indikation: KolorektalkarzinomMammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

STEFANO
2018

Carfilzomib in combination with lenalidomide and dexamethasone or carfilzomib in combination with dexamethasone alone in patients with multiple myeloma who have received at least one prior therapy: Interim results of the non-interventional CARO study.

Knauf, W., Ammon, A., Merling, M., Hurtz, H.-J., Vannier, C., Schulz, H., Marschner, N., Riedt, T., Potthoff, K., 2018.

Oncol Res Treat 41 (suppl 4)(P572).

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

CARO
2018

Does progression influence the quality of life? – Data from patients with advanced breast cancer from the MaLife-Project.

Marschner N., Söling, U., Scholz, H., Azeh, I., Chiabudini, M., Kruggel, L., Jänicke, M., 2018.

Oncol Res Treat 41 (suppl.4) (V493)

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2018

1st-line therapy of patients with Waldenström Macroglobulinemia: Treatment reality and outcome data from the German prospective TLN Registry.

Knauf, W., Slawik, H.R., Bückner, U., Houet, L., Wetzel, N., Jänicke, M., Marschner, N., 2018.

Oncol Res Treat 41 (suppl 4)(P181), 47-48

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2018

MYRIAM: Prospective, intersectoral Real World cohort study for treatment and outcome of myeloma patients in Germany.

Knauf, W., Engelhardt, M., Lipke, J., Losem, C., Kasper, C., Dörfel, S., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

Oncol Res Treat 41 (suppl 4)(P574), 190.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

MYRIAM
2018

Survival of Non-Transplant Patients with Multiple Myeloma in Routine Care Differs from That in Clinical Trials—data from the Prospective German Tumour Registry Lymphatic Neoplasms.

Knauf, W., A. Aldaoud, U. Hutzschenreuter, M. Klausmann, S. Dille, N. Wetzel, M. Jänicke, N. Marschner, and the TLN-Group (Tumour Registry Lymphatic Neoplasms).

Annals of Hematology, 1 August 2018, 1–9. https://doi.org/10.1007/s00277-018-3449-8.

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Annals of Hematology

TLN
2018

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., the TMK-Group (Tumour Registry Breast Cancer), 2018.

Breast Cancer Res Treat 167(2), 567–578. doi:10.1007/s10549-017-4534-8

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2018

Results from the Prospective German TPK Clinical Cohort Study: Treatment Algorithms and Survival of 1,174 Patients with Locally Advanced, Inoperable or Metastatic Pancreatic Ductal Adenocarcinoma.

Hegewisch‐Becker, Susanna, Ali Aldaoud, Thomas Wolf, Beate Krammer‐Steiner, Hartmut Linde, Renate Scheiner‐Sparna, David Hamm, Martina Jänicke, and Norbert Marschner, 2018.

Epub ahead of print: International Journal of Cancer 0, no. ja. Accessed 19 July 2018. https://doi.org/10.1002/ijc.31751.

Indikation: Pankreaskarzinom; Veranstaltung: -; Journal: International Journal of Cancer

TPK
2018

Final Effectiveness and Safety Results of NABUCCO – Real-World Data from a Non-Interventional, Prospective, Multi-Center Study in 697 Patients with Metastatic Breast Cancer Treated with Nab-Paclitaxel.

Marschner, N., C. Salat, U. Söling, R. Hansen, S. Grebhardt, J. Harde, A. Nusch, and K. Potthoff.

Epub ahead of print: Clinical Breast Cancer 0, no. 0 (15 July 2018). https://doi.org/10.1016/j.clbc.2018.07.010.

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Clinical Breast Cancer

NABUCCO
2018

A brief instrument to measure health-related quality of life in patients with bone metastasis: validation of the German version of Bone Metastases Quality-of-Life-10 (BOMET-QoL-10).

Marschner, N., Wilke, J., Reschke, D., Kaiser, F., Schmoor, C., Grugel, R., Boller, E., 2018.

Epub ahead of print: Journal of Medical Economics 1–19. doi:10.1080/13696998.2018.1484750

Indikation: Sonstige; Veranstaltung: -; Journal: Journal of Medical Economics

ARIE
2018

Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.

Indikation: Sonstige; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

OTILIA
2018

The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Vannier, C., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2018.

HemaSphere 2(S1)(PB2162), 967.

Indikation: Hämoblastosen; Veranstaltung: EHA; Journal: -

MYRIAM
2018

MANTA – A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., Brunt, A.M., Kuemmel, S., Cabrero, I.R., Perelló, A., Kendall, A., Brown, J., Kristeleit, H., Conibear, J., Saura, C., Grenier, J., Máhr, K., Schenker, M., Sohn, J.H., Lee, K.S., Sarker, S.-J., Coetzee, C., Mousa, K., Castan, J.C., 2018.

Cancer Res 78(4 Supplement), GS2-07-GS2-07. doi:10.1158/1538-7445.SABCS17-GS2-07

Indikation: Mammakarzinom; Veranstaltung: SABCS; Journal: Cancer Research

MANTA
2018

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

Knauf, W., Aldaoud, A., Losem, C., Mittermueller, J., Neise, M., Niemeier, B., Harde, J., Trarbach, T., Potthoff, K., 2018.

Leuk. Res. 68, 90–97. doi:10.1016/j.leukres.2018.03.008

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Leukemia Research

Revlimid-NIS
2018

705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Mammakarzinom; Veranstaltung: DKK; Journal:

NABUCCO
2018

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Indikation: Bronchialkarzinom; Veranstaltung: -; Journal: BMC Cancer

REASON
2018

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel, S., Steffens, C.-C., Meyer, D., Tesch, H., Kruggel, L., Frank, M., Jänicke, M., Marschner, M. 2017.

Breast Cancer, 4 December 2017, 1–9. https://doi.org/10.1007/s12282-017-0823-7.

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer

TMK
2017

Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Losem, C., Ketzler-Henkel, Zahn, M., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., deWit, M., Metzenmacher, M., Waller, C., Kern, J., Weichert, W., Sebastian, M., Thomas, M., 2017.

IASLC World Conference (Yokohama) (P3.01-088).

Indikation: Bronchialkarzinom; Veranstaltung: IASLC (WCLC); Journal: -

CRISP
2017

Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Schirmacher, P., Sebastian, M., Thomas, M., 2017.

7th European Lung Cancer Conference (ELCC) (125P).

Indikation: Bronchialkarzinom; Veranstaltung: ELCC (IASLC); Journal: -

CRISP
2017

Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer – results from the prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P600), 174.

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2017

Treatment reality and outcome data of patients with advanced papillary cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Goebell, P., Müller, L., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P339), 96.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Systemic palliativ treatment and outcome in later lines in patients with metastatic colorectal cancer – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Schnell, R., Uhlig, J., Eggers, E., Jänicke, M., Fleitz, A., Wetzel, N., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P587).

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2017

How much does fatigue, pain and treatment time interfere with daily life of patients with breast cancer? – Data from the MaLife-Project.

Marschner, N., Scholz, H., Behringer, J., Frank, M., Kruggel, L., Jänicke, M., for the TMK Registry Group, 2017.

Oncol Res Treat 40(suppl 3)(V796), 226. doi:10.1159/000479566

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2017

Treatment of patients with multiple myeloma selected for high-dose chemotherapy and autologous stem cell transplantation – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Tamm, I., Anhuf, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P608), 178.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2017

Treatment sequences in patients with advanced or metastatic pancreatic cancer in German outpatient cancer centers – data from the TPK clinical cohort study.

Hegewisch-Becker, S., Aldaoud, A., Lerchenmüller, C., Scheiner-Sparna, R., Jänicke, M., Hamm, D., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P825), 235.

Indikation: Pankreaskarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TPK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(V420), 114.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017.

Oncol Res Treat 40 (suppl 3)(P343), 97–98.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PAZOREAL
2017

German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

IDELA
2017

Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Kolorektalkarzinom; Veranstaltung: ISPOR; Journal: -

TKK
2017

Clinical Comparison of first-line platin chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data.

Haas, J., Meise, D., Ogbonnaya, A., Eaddy, M., Daeßler, K., Sandner, R., Binninger, A., Jaenicke, M., Chiabudini, M., Marschner, N., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Bronchialkarzinom; Veranstaltung: ISPOR; Journal: -

TLK
2017

Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Müller, L., Goebell, P. J., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(909P).

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P. J., Müller, L., Staehler, M., Müller, M., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(902P). doi:10.1093/annonc/mdx365

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Ann Oncol 28 (suppl 5)(1370P), 490.

Indikation: Bronchialkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TLK
2017

CRISP
2017

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com